Targeting LINC070974 inhibits lung adenocarcinoma cell proliferation and progression by interacting with Y-box binding protein 1

• Knockdown of LINC070974 inhibits NSCLC cell proliferation, migration, invasion, and tumor formation in vitro and in vivo. • LINC070974 silencing enhances cisplatin efficacy in drug-resistant A549/DDP cells. • LINC070974 interacts with YBX1 to regulate CCND1 expression and p53 signaling pathway. • Nebulized inhalation of siRNA targeting LINC070974 suppresses lung tumor growth and metastasis, offering a novel therapeutic strategy.